Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

Helen E. Heslop, Karen S. Slobod, Martin A. Pule, Gregory A. Hale, Alexandra Rousseau, Colton A. Smith, Catherine M. Bollard, Hao Liu, Meng Fen Wu, Richard J. Rochester, Persis J. Amrolia, Julia L. Hurwitz, Malcolm K. Brenner, Cliona M. Rooney

Research output: Contribution to journalArticle

490 Citations (Scopus)

Abstract

T-cell immunotherapy that takes advantage of Epstein-Barr virus (EBV)-stimulated immunity has the potential to fill an important niche in targeted therapy for EBV-related cancers. To address questions of long-term efficacy, safety, and practicality, we studied 114 patients who had received infusions of EBV-specific cytotoxic T lymphocytes (CTLs) at 3 different centers to prevent or treat EBV + lymphoproliferative disease (LPD) arising after hematopoietic stem cell transplantation. Toxicity was minimal, consisting mainly of localized swelling at sites of responsive disease. None of the 101 patients who received CTL prophylaxis developed EBV + LPD, whereas 11 of 13 patients treated with CTLs for biopsy-proven or probable LPD achieved sustained complete remissions. The gene-marking component of this study enabled us to demonstrate the persistence of functional CTLs for up to 9 years. A preliminary analysis indicated that a patientspecific CTL line can be manufactured, tested, and infused for $6095, a cost that compares favorably with other modalities used in the treatment of LPD. We conclude that the CTL lines described here provide safe and effective prophylaxis or treatment for lymphoproliferative disease in transplantation recipients, and the manufacturing methodology is robust and can be transferred readily from one institution to another without loss of reproducibility. The current trial was registered at www.clinicaltrials. gov as #NCT00058812.

Original languageEnglish (US)
Pages (from-to)925-935
Number of pages11
JournalBlood
Volume115
Issue number5
DOIs
StatePublished - Feb 4 2010
Externally publishedYes

Fingerprint

Transplants
T-cells
Cytotoxic T-Lymphocytes
Human Herpesvirus 4
Viruses
T-Lymphocytes
Virus Diseases
Gene Components
Hematopoietic Stem Cell Transplantation
Biopsy
Immunotherapy
Transplant Recipients
Stem cells
Immunity
Therapeutics
Transplantation
Toxicity
Swelling
Genes
Safety

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Heslop, H. E., Slobod, K. S., Pule, M. A., Hale, G. A., Rousseau, A., Smith, C. A., ... Rooney, C. M. (2010). Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood, 115(5), 925-935. https://doi.org/10.1182/blood-2009-08-239186

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. / Heslop, Helen E.; Slobod, Karen S.; Pule, Martin A.; Hale, Gregory A.; Rousseau, Alexandra; Smith, Colton A.; Bollard, Catherine M.; Liu, Hao; Wu, Meng Fen; Rochester, Richard J.; Amrolia, Persis J.; Hurwitz, Julia L.; Brenner, Malcolm K.; Rooney, Cliona M.

In: Blood, Vol. 115, No. 5, 04.02.2010, p. 925-935.

Research output: Contribution to journalArticle

Heslop, HE, Slobod, KS, Pule, MA, Hale, GA, Rousseau, A, Smith, CA, Bollard, CM, Liu, H, Wu, MF, Rochester, RJ, Amrolia, PJ, Hurwitz, JL, Brenner, MK & Rooney, CM 2010, 'Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients', Blood, vol. 115, no. 5, pp. 925-935. https://doi.org/10.1182/blood-2009-08-239186
Heslop, Helen E. ; Slobod, Karen S. ; Pule, Martin A. ; Hale, Gregory A. ; Rousseau, Alexandra ; Smith, Colton A. ; Bollard, Catherine M. ; Liu, Hao ; Wu, Meng Fen ; Rochester, Richard J. ; Amrolia, Persis J. ; Hurwitz, Julia L. ; Brenner, Malcolm K. ; Rooney, Cliona M. / Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. In: Blood. 2010 ; Vol. 115, No. 5. pp. 925-935.
@article{7a57f568c59f4046bb3173dee3f6fc4a,
title = "Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients",
abstract = "T-cell immunotherapy that takes advantage of Epstein-Barr virus (EBV)-stimulated immunity has the potential to fill an important niche in targeted therapy for EBV-related cancers. To address questions of long-term efficacy, safety, and practicality, we studied 114 patients who had received infusions of EBV-specific cytotoxic T lymphocytes (CTLs) at 3 different centers to prevent or treat EBV + lymphoproliferative disease (LPD) arising after hematopoietic stem cell transplantation. Toxicity was minimal, consisting mainly of localized swelling at sites of responsive disease. None of the 101 patients who received CTL prophylaxis developed EBV + LPD, whereas 11 of 13 patients treated with CTLs for biopsy-proven or probable LPD achieved sustained complete remissions. The gene-marking component of this study enabled us to demonstrate the persistence of functional CTLs for up to 9 years. A preliminary analysis indicated that a patientspecific CTL line can be manufactured, tested, and infused for $6095, a cost that compares favorably with other modalities used in the treatment of LPD. We conclude that the CTL lines described here provide safe and effective prophylaxis or treatment for lymphoproliferative disease in transplantation recipients, and the manufacturing methodology is robust and can be transferred readily from one institution to another without loss of reproducibility. The current trial was registered at www.clinicaltrials. gov as #NCT00058812.",
author = "Heslop, {Helen E.} and Slobod, {Karen S.} and Pule, {Martin A.} and Hale, {Gregory A.} and Alexandra Rousseau and Smith, {Colton A.} and Bollard, {Catherine M.} and Hao Liu and Wu, {Meng Fen} and Rochester, {Richard J.} and Amrolia, {Persis J.} and Hurwitz, {Julia L.} and Brenner, {Malcolm K.} and Rooney, {Cliona M.}",
year = "2010",
month = "2",
day = "4",
doi = "10.1182/blood-2009-08-239186",
language = "English (US)",
volume = "115",
pages = "925--935",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

AU - Heslop, Helen E.

AU - Slobod, Karen S.

AU - Pule, Martin A.

AU - Hale, Gregory A.

AU - Rousseau, Alexandra

AU - Smith, Colton A.

AU - Bollard, Catherine M.

AU - Liu, Hao

AU - Wu, Meng Fen

AU - Rochester, Richard J.

AU - Amrolia, Persis J.

AU - Hurwitz, Julia L.

AU - Brenner, Malcolm K.

AU - Rooney, Cliona M.

PY - 2010/2/4

Y1 - 2010/2/4

N2 - T-cell immunotherapy that takes advantage of Epstein-Barr virus (EBV)-stimulated immunity has the potential to fill an important niche in targeted therapy for EBV-related cancers. To address questions of long-term efficacy, safety, and practicality, we studied 114 patients who had received infusions of EBV-specific cytotoxic T lymphocytes (CTLs) at 3 different centers to prevent or treat EBV + lymphoproliferative disease (LPD) arising after hematopoietic stem cell transplantation. Toxicity was minimal, consisting mainly of localized swelling at sites of responsive disease. None of the 101 patients who received CTL prophylaxis developed EBV + LPD, whereas 11 of 13 patients treated with CTLs for biopsy-proven or probable LPD achieved sustained complete remissions. The gene-marking component of this study enabled us to demonstrate the persistence of functional CTLs for up to 9 years. A preliminary analysis indicated that a patientspecific CTL line can be manufactured, tested, and infused for $6095, a cost that compares favorably with other modalities used in the treatment of LPD. We conclude that the CTL lines described here provide safe and effective prophylaxis or treatment for lymphoproliferative disease in transplantation recipients, and the manufacturing methodology is robust and can be transferred readily from one institution to another without loss of reproducibility. The current trial was registered at www.clinicaltrials. gov as #NCT00058812.

AB - T-cell immunotherapy that takes advantage of Epstein-Barr virus (EBV)-stimulated immunity has the potential to fill an important niche in targeted therapy for EBV-related cancers. To address questions of long-term efficacy, safety, and practicality, we studied 114 patients who had received infusions of EBV-specific cytotoxic T lymphocytes (CTLs) at 3 different centers to prevent or treat EBV + lymphoproliferative disease (LPD) arising after hematopoietic stem cell transplantation. Toxicity was minimal, consisting mainly of localized swelling at sites of responsive disease. None of the 101 patients who received CTL prophylaxis developed EBV + LPD, whereas 11 of 13 patients treated with CTLs for biopsy-proven or probable LPD achieved sustained complete remissions. The gene-marking component of this study enabled us to demonstrate the persistence of functional CTLs for up to 9 years. A preliminary analysis indicated that a patientspecific CTL line can be manufactured, tested, and infused for $6095, a cost that compares favorably with other modalities used in the treatment of LPD. We conclude that the CTL lines described here provide safe and effective prophylaxis or treatment for lymphoproliferative disease in transplantation recipients, and the manufacturing methodology is robust and can be transferred readily from one institution to another without loss of reproducibility. The current trial was registered at www.clinicaltrials. gov as #NCT00058812.

UR - http://www.scopus.com/inward/record.url?scp=77649221824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649221824&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-08-239186

DO - 10.1182/blood-2009-08-239186

M3 - Article

C2 - 19880495

AN - SCOPUS:77649221824

VL - 115

SP - 925

EP - 935

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -